

Company Overview

Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer. We believe our therapies have the potential to significantly impact cancer treatment and the clinical outcomes for people with cancer.

We have developed a proprietary T-cell receptor (TCR) platform that enables us to identify cancer targets, as well as genetically engineer TCRs to recognize and attack these cancer targets. We engineer a patient's own T-cells to express these affinity-enhanced TCRs, to produce TCR T-cell treatments that we call SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapies. We plan to submit our first Biologics License Application (BLA) by the end of 2022 for afamitresgene autoleucel ("afamicelel"; formerly ADP-A2M4) for the treatment of people with synovial sarcoma.

Our translational science team evaluates our manufactured products, as well as patients' tumor and blood samples collected both before and after SPEAR T-cell therapy. This enables us to monitor how our SPEAR T-cells perform and persist in patients, and to examine how these data relate to clinical responses. Data from our translational research has led to the development of multiple next-generation approaches. Our first next-generation cell therapy targeting MAGE-A4, ADP-A2M4CD8, is currently being evaluated in the SURPASS family of trials.

Further, we have a deep preclinical pipeline with multiple autologous and allogeneic cell therapy approaches, including new next-generation SPEAR T-cells, additional TCR targets, broader HLA coverage, HLA Independent TCR (HiTs) cell therapies that eliminate the need for HLA; and next-generation Tumor Infiltrating Lymphocyte (TIL) therapies.

Cell therapy demands specific internal capabilities. Adaptimmune has been built as an integrated cell therapy company, from the ground up, with the sole purpose of designing and delivering cell therapies for people with cancer.

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Apr 12 2024, 8:00 AM EDT

Results of Adaptimmune's SPEARHEAD-1 Trial with Afamicelel in Advanced Sarcomas Published in the Lancet

Mar 27 2024, 7:30 PM EDT

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Mar 6 2024, 7:00 AM EST

Adaptimmune

351 Rouse Boulevard
Philadelphia, PA 19112
USA

Stock Overview

Symbol	ADAP
Exchange	Nasdaq
Market Cap	241.07m
Last Price	\$0.97
52-Week Range	\$0.42 - \$2.05

Investor Relations

T: 215-825-9306
IR@adaptimmune.com

04/19/2024 04:00 PM EDT

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.